Fisher BioServices provides biobanking services to CCFA to help accelerate the development of personalized medicine for patients with IBD

Biobank

The Crohn’s & Colitis Foundation of America (CCFA) announces a three-year, $17.5 million grant from The Leona M. and Harry B. Helmsley Charitable Trust to establish an integrated knowledge platform designed to centralize and aggregate patient information – with linked biosamples – across multiple research efforts. The new initiative, called IBD Plexus, is designed to speed progress toward precision medicine through novel research, leading to better diagnostics, treatments and, ultimately, cures for Crohn’s disease and ulcerative colitis, also known as inflammatory bowel diseases (IBD).

IBD Plexus (named for its complex network of parts) involves every IBD stakeholder, including academic and industry researchers, patients of all ages, and clinicians and other healthcare providers. The initiative forms and nurtures collaboration and cooperation among stakeholders, and is powered by their common drive toward better care, treatments and a cure. 

IBD Plexus’ biobanking services are being provided by Thermo Fisher Scientific, the leader in serving science, through its Fisher BioServices brand. Fisher BioServices operates an extensive network of biobanking facilities, and manages hundreds of millions of samples worldwide. “We employ cutting-edge biobanking solutions and information technology for leading research and therapy development organizations worldwide,” said Dennis Barger, Vice President and General Manager, Fisher BioServices, for Thermo Fisher Scientific. “We are pleased to participate in CCFA’s IBD Plexus, and join in their grand vision of delivering personalized medicine to patients. Our services will enable a global network of researchers to accelerate effective treatment development and discovery of a cure for IBD.”

To read more, please click here.